2026-06-18

OSINT: Iranian Geopolitical Tensions Escalate, Raising Regional Risk

CFTC SILVER speculators at extreme short: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

Silver bear 7.0% vs prior close ($70.70 → $65.78)

Gold -2.82%: significant decline on the session

OSINT: NATO Signals Heightened European Geopolitical Tensions

CFTC SILVER speculators at extreme short: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

Oil -3.89%: significant decline on the session

OSINT: US casualties in Iran campaign coincide with record‑high stock market

CFTC SILVER speculators at extreme short: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

OSINT: Trump signs MOU to end Iran conflict, White House says

CFTC SILVER speculator at extreme short — contrarian bull signal

CFTC BITCOIN speculator at extreme long — contrarian bear signal

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

Oil -1.73%: significant decline on the session

OSINT: Ukrainian drones strike Moscow, forcing air traffic diversions

Platinum bear 5.0% vs prior close ($1,790.70 → $1,701.80)

Coffee bear 4.3% vs prior close ($277.85 → $265.80)

SOL open interest +162.4% — OI surge

BTC open interest +225.2% — OI surge

ETH open interest +217.9% — OI surge

SOL open interest -63.0% — OI collapse

BTC open interest -44.1% — OI collapse

ETH open interest -66.5% — OI collapse

SOL open interest +305.0% — OI surge

ETH open interest -67.2% — OI collapse

BTC open interest +252.4% — OI surge

SPYx/USDC has $67.0M volume but only $515K liquidity — thin market, slippage risk

BTC open interest -42.3% — OI collapse

SOL open interest +307.5% — OI surge

ETH open interest -67.3% — OI collapse

ETH DEX volume/liquidity ratio elevated (0.53x): on-chain trade volume 0.53x liquidity

OSINT: DOJ Seeks Court Block on Historic US Reparations Program

ETH DEX volume/liquidity ratio elevated (0.51x): on-chain trade volume 0.51x liquidity

Phase 3 trial terminated early — JOHNSON Topiramate: Long-Term Maintenance of Weight Loss Induced by Low-Calorie Diet in

Phase 3 trial terminated early — JOHNSON GeneSearch™ Breast Lymph Node (BLN) Assay China Registration Study

Phase 3 trial terminated early — ELI A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic

Phase 3 trial terminated early — ELI A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melano

Phase 3 trial terminated early — BRISTOL A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus S

Phase 3 trial terminated early — BIOGEN A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared

Phase 3 trial terminated early — BIOGEN Natalizumab (Tysabri) Re-Initiation of Dosing

Phase 3 trial terminated early — BIOGEN Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Pati

Phase 3 trial terminated early — AMGEN Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout

Phase 3 trial terminated early — AMGEN MONET1-MOtesanib NSCLC Efficacy and Tolerability Study

Phase 3 trial terminated early — AMGEN AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

Phase 3 trial terminated early — AMGEN Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Stati

Phase 3 trial terminated early — Medtronic Lumbar Interbody Fusion Using the Telamon® Peek™ Versus the Telamon® Hydrosorb™

Phase 3 trial terminated early — AbbVie A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azaciti

Phase 3 trial terminated early — Merck Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)

Phase 3 trial terminated early — Merck Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterole

Phase 3 trial terminated early — Merck Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo f

Phase 3 trial terminated early — Merck Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensa

Phase 3 trial terminated early — Merck Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

Phase 3 trial terminated early — PFIZER A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing

Phase 3 trial terminated early — PFIZER A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treat

Phase 3 trial terminated early — PFIZER Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk

Phase 3 trial terminated early — PFIZER Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Pati

Phase 3 trial terminated early — PFIZER Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain

Phase 3 trial terminated early — PFIZER A Study to Understand the Long-term Safety and Effects of an Experimental Gene T

Phase 3 trial terminated early — ABBOTT Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral

Phase 3 trial terminated early — ABBOTT Femtosecond Laser for Cataract Surgery

Phase 3 trial terminated early — ABBOTT Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients

Phase 3 trial terminated early — ABBOTT Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascul

Phase 3 trial terminated early — ABBOTT BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r)

Phase 3 trial terminated early — GILEAD Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic

Phase 3 trial terminated early — GILEAD (mo)BETTA Trial in Transwomen for Optimization of ART

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Activist 13D filing — shareholder value

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

PORTLAND GENERAL ELECTRIC CO /OR/ search volume spiked +100 pts — unusual interest

GE Vernova Inc. search volume spiked +100 pts — unusual interest

KLA CORP search volume spiked +39 pts — unusual interest

LINDE PLC search volume spiked +100 pts — unusual interest

MSFT RSI 18.9 — oversold (crossed below 30)

Strategy Inc search volume spiked +26 pts — unusual interest

GE Vernova Inc. search volume spiked +100 pts — unusual interest

KLA CORP search volume spiked +39 pts — unusual interest

LINDE PLC search volume spiked +100 pts — unusual interest

Q1-2026: Beat consensus by 16.0% — EPS $-0.33 vs $-0.3927 estimate

Q4-2025: Missed consensus by 58.7% — EPS $-0.68 vs $-0.4284 estimate

Q2-2025: Missed consensus by 5586.3% — EPS $-0.29 vs $-0.0051 estimate

Q2-2025: Beat consensus by 24.6% — EPS $0.2 vs $0.1605 estimate

Q4-2024: Missed consensus by 5.2% — EPS $0.574 vs $0.6056 estimate

Q4-2025: Beat consensus by 10.5% — EPS $0.4428 vs $0.4007 estimate

Q2-2025: Beat consensus by 13.5% — EPS $0.629 vs $0.5542 estimate

Q4-2025: Beat consensus by 18.8% — EPS $1.22 vs $1.0272 estimate

Q2-2025: Missed consensus by 74.4% — EPS $0.23 vs $0.8989 estimate

Q1-2026: Beat consensus by 18.2% — EPS $0.8 vs $0.6767 estimate

Q4-2025: Missed consensus by 53.9% — EPS $0.67 vs $1.4544 estimate

Q4-2025: Beat consensus by 24.4% — EPS $1.06 vs $0.8524 estimate

Missed consensus by 8.6% — EPS $0.65 vs $0.711 estimate

Beat consensus by 76.5% — EPS $0.03 vs $0.017 estimate

Q4-2026: Beat consensus by 65.3% — EPS $0.04 vs $0.0242 estimate

Q2-2026: Beat consensus by 420.2% — EPS $0.09 vs $0.0173 estimate

Q3-2026: Beat consensus by 206.1% — EPS $0.06 vs $0.0196 estimate

Q4-2024: Missed consensus by 100.0% — EPS $0 vs $0.0051 estimate

Q1-2025: Missed consensus by 198.0% — EPS $-0.01 vs $0.0102 estimate

Q3-2026: Missed consensus by 58.6% — EPS $-3.26 vs $-2.0553 estimate

Q2-2026: Missed consensus by 874.0% — EPS $-6.11 vs $-0.6273 estimate

Q1-2026: Beat consensus by 15.7% — EPS $-0.55 vs $-0.6528 estimate

Q1-2026: Beat consensus by 21.4% — EPS $0.26 vs $0.2142 estimate

Q1-2026: Beat consensus by 12.0% — EPS $0.24 vs $0.2142 estimate

Q2-2025: Beat consensus by 50.5% — EPS $0.22 vs $0.1462 estimate

Q3-2025: Missed consensus by 15.2% — EPS $0.16 vs $0.1887 estimate

Q2-2025: Beat consensus by 55.4% — EPS $-0.15 vs $-0.3363 estimate

Q1-2026: Missed consensus by 14.8% — EPS $-1.17 vs $-1.0196 estimate

Q4-2025: Missed consensus by 20.8% — EPS $-0.93 vs $-0.7701 estimate

Q3-2025: Missed consensus by 29.3% — EPS $-0.51 vs $-0.3944 estimate

Q2-2026: Missed consensus by 9.2% — EPS $0.68 vs $0.7486 estimate

Q3-2026: Beat consensus by 13.1% — EPS $1.27 vs $1.1228 estimate

Q1-2026: Beat consensus by 10.2% — EPS $1.95 vs $1.7692 estimate

Q2-2026: Beat consensus by 17.1% — EPS $1.97 vs $1.6817 estimate

Q4-2026: Beat consensus by 11.7% — EPS $1.07 vs $0.9581 estimate

Q3-2019: Missed consensus by 191.3% — EPS $-0.03 vs $-0.0103 estimate

Q4-2019: Beat consensus by 51.5% — EPS $-0.01 vs $-0.0206 estimate

Q4-2019: Missed consensus by 191.3% — EPS $-0.06 vs $-0.0206 estimate

Q3-2009: Beat consensus by 19.6% — EPS $0.58 vs $0.4848 estimate

Q4-2009: Missed consensus by 11.7% — EPS $0.58 vs $0.6565 estimate

Missed consensus by 7.6% — EPS $0.56 vs $0.606 estimate

Q1-2026: Missed consensus by 9.7% — EPS $0.33 vs $0.3655 estimate

Q2-2026: Beat consensus by 25.4% — EPS $0.34 vs $0.2712 estimate

Q3-2025: Missed consensus by 110.9% — EPS $-0.03 vs $0.2749 estimate

Q4-2025: Missed consensus by 37.4% — EPS $0.21 vs $0.3356 estimate

Q2-2025: Missed consensus by 6.3% — EPS $0.45 vs $0.4801 estimate

Q4-2025: Beat consensus by 25.3% — EPS $0.72 vs $0.5746 estimate

Q3-2026: Beat consensus by 11.7% — EPS $0.97 vs $0.8686 estimate

Q2-2026: Beat consensus by 12.3% — EPS $1.1 vs $0.9797 estimate

Q1-2027: Missed consensus by 42.1% — EPS $0.07 vs $0.1209 estimate

Q3-2026: Beat consensus by 28.7% — EPS $0.21 vs $0.1632 estimate

Q4-2026: Missed consensus by 36.8% — EPS $-1.3 vs $-0.9506 estimate

Q3-2025: Missed consensus by 6.4% — EPS $0.42 vs $0.4488 estimate

Q2-2025: Missed consensus by 11.7% — EPS $0.41 vs $0.4641 estimate

Q1-2026: Missed consensus by 8.8% — EPS $0.4 vs $0.4386 estimate

Q3-2025: Missed consensus by 214.0% — EPS $-0.29 vs $0.2544 estimate

Q1-2026: Missed consensus by 264.8% — EPS $-0.77 vs $-0.2111 estimate

Beat consensus by 79.9% — EPS $-0.29 vs $-1.441 estimate

Missed consensus by 191.8% — EPS $-0.09 vs $0.098 estimate

Q4-2021: Beat consensus by 100.0% — EPS $0 vs $-0.0103 estimate

Q1-2026: Beat consensus by 35.4% — EPS $4.17 vs $3.0804 estimate

Q2-2025: Missed consensus by 29.4% — EPS $2.29 vs $3.2436 estimate

Q4-2025: Missed consensus by 55.3% — EPS $1.54 vs $3.4476 estimate

Q3-2025: Beat consensus by 8.0% — EPS $3.68 vs $3.4068 estimate

Q1-2026: Beat consensus by 42.9% — EPS $1.21 vs $0.8466 estimate

Q4-2025: Beat consensus by 83.2% — EPS $1.57 vs $0.8568 estimate

Q1-2026: Beat consensus by 7.5% — EPS $0.91 vs $0.8466 estimate

Q2-2025: Beat consensus by 105.7% — EPS $1.5 vs $0.7293 estimate

Q2-2025: Beat consensus by 16.6% — EPS $-0.71 vs $-0.8517 estimate

Q4-2025: Missed consensus by 30.1% — EPS $-0.71 vs $-0.5457 estimate

Missed consensus by 37.9% — EPS $-0.75 vs $-0.544 estimate

Missed consensus by 14.9% — EPS $-20.4 vs $-17.748 estimate

Q1-2026: Missed consensus by 32.7% — EPS $-1.99 vs $-1.4994 estimate

Q2-2025: Beat consensus by 58.9% — EPS $-20.04 vs $-48.7152 estimate

Q4-2025: Beat consensus by 77.3% — EPS $-2.06 vs $-9.0576 estimate

Q3-2025: Missed consensus by 11.9% — EPS $0.54 vs $0.6127 estimate

Q2-2025: Beat consensus by 20.9% — EPS $0.59 vs $0.4882 estimate

Q1-2026: Beat consensus by 137.0% — EPS $0.75 vs $0.3165 estimate

Q4-2025: Missed consensus by 36.8% — EPS $0.3 vs $0.4747 estimate

Q1-2026: Beat consensus by 14.2% — EPS $0.77 vs $0.6745 estimate

Q2-2025: Beat consensus by 236.9% — EPS $0.19 vs $0.0564 estimate

Beat consensus by 10.2% — EPS $0.78 vs $0.708 estimate

Beat consensus by 38.5% — EPS $0.55 vs $0.397 estimate

Q3-2025: Beat consensus by 13.2% — EPS $1.68 vs $1.4846 estimate

Q1-2026: Missed consensus by 46.1% — EPS $0.68 vs $1.2611 estimate

Q4-2025: Beat consensus by 25.2% — EPS $1.81 vs $1.4454 estimate

Q2-2025: Beat consensus by 30.1% — EPS $2.28 vs $1.7529 estimate

Q3-2026: Missed consensus by 10.2% — EPS $2.97 vs $3.3074 estimate

Q1-2026: Missed consensus by 11.6% — EPS $0.53 vs $0.5993 estimate

Q2-2025: Missed consensus by 23.0% — EPS $0.49 vs $0.6363 estimate

Q4-2025: Missed consensus by 5.2% — EPS $0.6 vs $0.6329 estimate

Missed consensus by 139.3% — EPS $-277 vs $-115.77 estimate

Missed consensus by 152.8% — EPS $-1045.55 vs $-413.61 estimate

OSINT: DOJ Seeks Court Block on Historic US Reparations Program

OSINT: Ukrainian drones strike Moscow, forcing air traffic diversions

DXY +0.72% — dollar strength signal

DXY +0.56% — dollar strength signal

OSINT: Ukrainian drones strike Moscow, forcing air traffic diversions